Dezide25 mg+50 mg

Approved Indications

Dezide is a fixed-dose combination of a thiazide diuretic (hydrochlorothiazide) and a potassium-sparing diuretic (triamterene). It is FDA-approved for use in patients for whom this specific combination is considered appropriate, generally including:

• Hypertension — for the treatment of high blood pressure, either alone or as an add-on when a single diuretic is insufficient or when a patient has developed or is at risk of hypokalemia on hydrochlorothiazide alone.
• Edema — for edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, and corticosteroid- or estrogen-induced fluid retention, particularly when maintenance of normal serum potassium is desirable.

Dezide is intended for patients in whom the combination of a kaliuretic (potassium-wasting) and a potassium-conserving diuretic is felt to be a clinically appropriate strategy — it is not first-line therapy for every patient with hypertension or edema, and the decision to use it should follow evaluation of individual electrolyte and renal status.

Each tablet of Hydrochlorothiazide + Triamterene is a fixed-dose combination typically available in two commonly used strengths (formulation and strength availability can vary by market/manufacturer):

• Hydrochlorothiazide 25 mg + Triamterene 37.5 mg
• Hydrochlorothiazide 50 mg + Triamterene 75 mg

Hydrochlorothiazide is a thiazide-type diuretic and triamterene is a potassium-sparing diuretic; they are combined to promote diuresis and blood pressure control while reducing the risk of thiazide-induced potassium loss.

Dezide is an oral fixed-dose diuretic (water pill) combination used mainly to treat high blood pressure and fluid retention (edema). It pairs hydrochlorothiazide, which promotes sodium, chloride, and water excretion but also causes potassium loss, with triamterene, which conserves potassium in the kidney's distal tubule. This pairing is designed to achieve the blood-pressure-lowering and fluid-reducing benefits of a thiazide diuretic while lowering the likelihood of thiazide-induced hypokalemia. Despite the potassium-sparing component, electrolyte imbalances (including hyperkalemia) can still occur, so periodic monitoring is required.

Dezide belongs to the therapeutic class of diuretic combinations — specifically a thiazide diuretic combined with a potassium-sparing diuretic, used as an antihypertensive and antiedema agent.

Mechanism of Action

Hydrochlorothiazide + Triamterene combines two diuretics with complementary and distinct mechanisms:

• Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule of the nephron by blocking the Na⁺/Cl⁻ cotransporter, increasing excretion of sodium, chloride, and water, and secondarily increasing potassium and magnesium excretion. Its antihypertensive mechanism also involves a reduction in plasma volume and, with chronic use, a decrease in peripheral vascular resistance.
• Triamterene acts on the distal renal tubule and collecting duct, directly blocking epithelial sodium channels (ENaC) independent of aldosterone. This reduces sodium reabsorption and, importantly, reduces potassium and hydrogen ion secretion, thereby conserving potassium that would otherwise be lost due to hydrochlorothiazide.

The net pharmacologic effect is diuresis and reduction of blood pressure and edema with a more neutral effect on serum potassium than a thiazide diuretic used alone — although hyperkalemia can still occur, particularly in patients with renal impairment or those on other potassium-elevating drugs.

Dezide should be taken by mouth, preferably with food to reduce stomach upset. It is best taken earlier in the day (e.g., with breakfast) to avoid the need to urinate during the night. Swallow the tablet whole with a glass of water unless the physician has advised otherwise. Maintain adequate but not excessive fluid intake, and avoid potassium supplements or salt substitutes containing potassium unless specifically directed by a physician.

Clinically Significant Drug Interactions

• ACE inhibitors, ARBs, potassium supplements, potassium-containing salt substitutes, and other potassium-sparing diuretics: co-administration with Dezide increases the risk of clinically significant hyperkalemia; concurrent use requires close monitoring of serum potassium.
• NSAIDs (including COX-2 inhibitors): may reduce the diuretic and antihypertensive effect of Dezide and increase the risk of renal impairment and hyperkalemia, especially in elderly or volume-depleted patients.
• Lithium: Dezide reduces renal clearance of lithium, increasing the risk of lithium toxicity; concurrent use is generally avoided or requires close lithium level monitoring.
• Other antihypertensive agents: additive blood-pressure-lowering effect; dose adjustment of either agent may be required.
• Digoxin: although the potassium-sparing component reduces the risk relative to a thiazide alone, significant electrolyte disturbances (hypokalemia or hyperkalemia) from diuretic therapy can still increase susceptibility to digoxin toxicity or arrhythmia.
• Corticosteroids and ACTH: may intensify electrolyte depletion (particularly sodium and, less so with the potassium-sparing component, potassium).
• Amantadine: triamterene can reduce renal clearance of amantadine, increasing risk of amantadine toxicity.
• Antidiabetic agents (including insulin): the thiazide component may reduce glycemic control, requiring dose adjustment.

Common Side Effects

• Dizziness, headache, and fatigue
• Nausea, vomiting, or gastrointestinal upset
• Muscle cramps or weakness
• Dry mouth or increased thirst
• Increased urination

Serious / Less Common Side Effects

• Hyperkalemia (elevated blood potassium) — see Precautions and Warnings
• Hyponatremia (low blood sodium) with confusion, lethargy, or seizures in severe cases
• Kidney stones and, rarely, acute interstitial nephritis related to triamterene
• Photosensitivity (increased skin sensitivity to sunlight)
• Hyperuricemia, which may precipitate a gout attack
• Hyperglycemia, particularly in patients with diabetes or prediabetes
• Blood disorders such as leukopenia or thrombocytopenia (rare)
• Hypersensitivity reactions, including rash or, rarely, severe skin reactions

Pregnancy: Dezide should be used during pregnancy only if clearly needed and the potential benefit to the mother justifies the potential risk to the fetus. Thiazide diuretics cross the placenta and have been associated with fetal or neonatal jaundice, thrombocytopenia, and other adverse effects, and diuretics do not prevent and may worsen conditions like pre-eclampsia. A physician should be consulted before use in pregnancy, and treatment of chronic hypertension in pregnancy is generally managed with agents with a better-established safety profile.

Lactation: Thiazide diuretics are excreted in breast milk and can suppress lactation; whether triamterene is excreted in human milk is not well established. Dezide should be used during breastfeeding only under medical supervision, weighing the benefits of treatment against potential risk to the nursing infant.

Key Precautions

• Hyperkalemia: despite its potassium-sparing component, Dezide can still cause dangerous hyperkalemia, particularly in patients with renal impairment, diabetes mellitus, the elderly, or those taking ACE inhibitors, ARBs, NSAIDs, or potassium supplements. Periodic serum potassium monitoring is recommended.
• Renal function: use with caution and close monitoring in patients with any degree of renal impairment; contraindicated if renal impairment is severe (see Contraindications).
• Hyponatremia and fluid/electrolyte imbalance: monitor for signs of dilutional or true hyponatremia, especially in elderly patients or those on a low-salt diet.
• Hyperuricemia/gout: the hydrochlorothiazide component can raise serum uric acid and precipitate gout in susceptible individuals.
• Hyperglycemia: blood glucose should be monitored in patients with diabetes or prediabetes, as thiazides can worsen glycemic control.
• Photosensitivity: minimize sun/UV exposure and use sun protection.
• Kidney stones and interstitial nephritis: triamterene has rarely been associated with kidney stone formation and acute interstitial nephritis; report flank pain, blood in urine, or reduced urine output promptly.
• Lithium therapy: avoid concurrent use where possible due to increased lithium toxicity risk (see Interactions).
• Hepatic impairment: use cautiously, as electrolyte shifts can precipitate hepatic coma.
• Systemic lupus erythematosus: thiazides have been reported to exacerbate or activate SLE.

Overdose with Dezide may cause severe electrolyte disturbances (hyperkalemia or hypokalemia, hyponatremia), dehydration, low blood pressure, dizziness, weakness, cardiac arrhythmias, and reduced kidney function. In case of a known or suspected overdose, seek immediate medical attention or contact a poison control center / emergency services right away. Treatment is supportive and should be carried out under medical supervision (e.g., correction of fluid and electrolyte imbalance, cardiac monitoring); do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Renal impairment: Dezide is contraindicated in anuria and severe renal impairment; use with caution and close monitoring in mild-to-moderate impairment due to elevated hyperkalemia risk.
• Hepatic impairment: use cautiously; diuretic-induced electrolyte changes can precipitate hepatic coma.
• Elderly: may be more sensitive to the blood-pressure-lowering, electrolyte, and renal effects; start at the lower end of the dosing range and monitor closely.
• Diabetes mellitus: monitor blood glucose, as thiazide diuretics can worsen glycemic control.
• Pediatric patients: safety and efficacy not established (see Pediatric Uses).

Duration of treatment with Dezide is individualized by the prescribing physician based on the condition being treated, blood pressure or edema response, and periodic monitoring of renal function and electrolytes. Hypertension and chronic edema often require long-term, ongoing therapy with regular follow-up visits and laboratory monitoring; the drug should not be stopped or the dose changed without medical advice.

Thiazide diuretic + Potassium-sparing diuretic (fixed-dose antihypertensive/diuretic combination)

Hydrochlorothiazide + Triamterene works through the combined action of hydrochlorothiazide (inhibits sodium/chloride reabsorption in the distal convoluted tubule, increasing sodium, chloride, water, and potassium excretion) and triamterene (blocks epithelial sodium channels in the distal tubule/collecting duct, reducing sodium reabsorption while conserving potassium). See Pharmacology for full details.

C

The safety and efficacy of Dezide have not been established in pediatric patients. Its use in children is generally not recommended, and it should only be considered in a pediatric patient if a physician specifically judges it necessary, with close monitoring of renal function, growth, and electrolytes.